NewzLondon-headquartered GSK announced the start of 'a three-year cost savings programme to simplify the organisation and reallocate capital and resources'. to discuss this with our people first."Stripping out the hit caused by camlipixant, GSK said its core operating profit rose 7% in the second quarter to £2.8 billion.Group revenue grew 5% to £8.4 billion."GSK has delivered another quarter of strong core results performance, with our key growth drivers performing well," Miels said in the earnings release."We remain focused on operational delivery, execution, and accelerating" research and development.Oncology again performed well, with sales up 18 percent.GSK in June announced a US$10.6-billion deal for Nuvalent, a Boston-based specialist in cancer treatments, furthering its push into both oncology and the US.UK investmentGSK separately announced Tuesday that it plans to invest £400 million on a new major R&D centre in university city Cambridge, eastern England.The site, to be operational by 2029, will serve the company's research and development in the UK with the help of more than 1,000 scientists."This investment by GSK is a vote of confidence in British business," new UK Prime Minister Andy Burnham said in a statement.It is "a boost for home grown innovati…
Summary from source